Loading
NYSEHealthcareMedical - Pharmaceuticals
Latest quote
$47.57
+$1.13 · +2.43%
Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.
Previous close
$47.57
+$1.13 · +2.43%
Regular session · ET · Market data may be delayed.
Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.
Day range
Current $47.57
52-week range
Current $47.57
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
83
Deep Value
Sentiment
52
Mixed
Risk
42
Elevated Risk
Momentum
30
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.
Day range
Current $47.57
52-week range
Current $47.57
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 1.09B USD | 1.14B USD | 1.13B USD | 1.13B USD | 1.09B USD |
| Cost of goods sold | 514.07M USD | 503.3M USD | 500.91M USD | 502.43M USD | 466.17M USD |
| Gross profit | 574.64M USD | 634.46M USD | 624.45M USD | 625.29M USD | 620.65M USD |
| Selling, general, and administrative | 265.23M USD | 263.93M USD | 259.47M USD | 252.42M USD | 264.8M USD |
| Operating expenses | 265.23M USD | 297.69M USD | 282.02M USD | 647.71M USD | 290.73M USD |
| Interest expense | 42.34M USD | 47.63M USD | 67.16M USD | 69.16M USD | 64.29M USD |
| Depreciation and amortization | 31.27M USD | 30.17M USD | 30.68M USD | 32.63M USD | 32.09M USD |
| Operating income | 309.41M USD | 336.78M USD | 342.43M USD | −22.42M USD | 329.92M USD |
| Net income | 190.3M USD | 214.61M USD | 209.34M USD | −82.31M USD | 205.38M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI78.47M0.00%2.3T USD0.03%$381.03-0.40%
iShares Russell 2000 ETFIWM57.91M0.07%78.56B USD0.19%$277.7-1.29%
Vanguard Morningstar Small-Cap ETFVB56.36M0.03%185.3B USD0.03%$286.98-1.41%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV38.56M0.14%26.69B USD0.33%$37.79-1.23%
Vanguard Morningstar Small-Cap Value ETFVBR35.84M0.05%68.2B USD0.05%$232.17-1.32%
Vanguard Extended Market ETFVXF28.47M0.03%95.4B USD0.05%$233.49-1.56%
Dimensional - US Targeted Value ETFDFAT20.48M0.07%30B USD0.33%$67.08-1.29%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM20.29M0.13%16.01B USD0.03%$53.28-1.32%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBU.S. Small Cap Value Portfolio ETF Class SharesDFSVVanguard Morningstar Small-Cap Value ETFVBRVanguard Extended Market ETFVXFDimensional - US Targeted Value ETFDFATState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
